Compare BHVN & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHVN | TMDX |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2022 | 2019 |
| Metric | BHVN | TMDX |
|---|---|---|
| Price | $13.75 | $92.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 13 |
| Target Price | $23.73 | ★ $104.55 |
| AVG Volume (30 Days) | ★ 3.0M | 1.1M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.08 | ★ 382.18 |
| EPS | N/A | ★ 1.08 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $26.70 |
| Revenue Next Year | N/A | $17.50 |
| P/E Ratio | ★ N/A | $85.37 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $7.99 | $60.11 |
| 52 Week High | $18.24 | $156.00 |
| Indicator | BHVN | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 67.27 |
| Support Level | $13.56 | $65.51 |
| Resistance Level | $15.27 | $92.93 |
| Average True Range (ATR) | 1.00 | 4.94 |
| MACD | -0.12 | 3.05 |
| Stochastic Oscillator | 12.82 | 84.04 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.